GSK repurchases 474,100 shares at 1,423p Avg; Treasury 5.81%

GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.

Rhea-AI Filing Summary

GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.

• Shares bought: 474,100 ordinary shares (nominal 31¼ p).
• Price range: 1,404.50–1,461.00 GBp; VWAP 1,423.11 GBp.
• Cumulative purchases since 4 June 2025: 18,910,038 shares.

The shares will be held in treasury, increasing the treasury balance to 237,044,421. Shares in issue (excluding treasury) now total 4,078,340,989, establishing the new denominator for voting-rights disclosures. Treasury stock represents 5.81 % of total voting rights.

No operational, earnings or guidance updates were provided; the filing primarily fulfils UK DTR 5.5.1R disclosure requirements.

Positive

• Continued execution of the authorised share-buyback programme demonstrates confidence in cash flow generation and provides incremental EPS accretion.

Negative

• Repurchased volume is immaterial versus 4.08 bn shares outstanding, limiting near-term impact on valuation or ownership structure.

Insights

Equity Analyst

TL;DR: Minor buyback disclosure; immaterial to valuation but signals ongoing capital return.

Today’s Form 6-K shows GSK purchased 474 k shares—roughly 0.01 % of the 4.08 bn float—at a 1,423 p VWAP. While the absolute cash outlay (~£6.7 m) is modest, the cumulative 18.9 m shares bought since 4 Jun equals ~0.46 % of shares outstanding, offering a marginal tail-wind to EPS and offsetting dilution from incentive schemes. Balance-sheet capacity remains ample; net debt/EBITDA ended 2024 at 1.3×, so repurchases should not constrain pipeline funding. From a market perspective the event is not impactful; it confirms program execution rather than changing forward fundamentals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GSK shares were repurchased on 31 July 2025?

GSK bought 474,100 ordinary shares.

What was the average price paid per share?

The volume-weighted average price was 1,423.11 GBp.

How many shares has GSK repurchased since 4 June 2025?

A total of 18,910,038 shares have been bought back under the programme.

What is GSK’s current share count excluding treasury shares?

Shares in issue now stand at 4,078,340,989.

What percentage of voting rights is held in treasury?

Post-transaction, treasury stock represents 5.81 % of total voting rights.

Will the repurchased shares be cancelled?

No, the shares will be held as treasury shares for potential future use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/01/2025 - 10:49 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through its corporate stockbroker, Merrill Lynch International (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase:	31 July 2025
Aggregate number of ordinary shares of 31¼ pence each purchased:	474,100
Lowest price paid per share (GBp):	1,404.50p
Highest price paid per share (GBp):	1,461.00p
Volume-weighted average price paid per share (GBp):	1,423.11p

The purchased shares will be held as Treasury shares.

Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 18,910,038 ordinary shares.

Following the above purchase, the Company will hold 237,044,421 ordinary shares in treasury and have 4,078,340,989 ordinary shares in issue (excluding Treasury shares).

The total number of voting rights in the Company is 4,078,340,989. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.81 per cent.

Detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme can be found at:

http://www.rns-pdf.londonstockexchange.com/rns/5000T_1-2025-7-31.pdf

Ends

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 01, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc